Iclusig Generic: When Will Generic Ponatinib Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Iclusig Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? 2029 to 2030 A wide window Why then?
- Has the FDA approved a generic? July 2023 Since discontinued Why not yet?
- When does the last patent end? December 2033 6 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic ponatinib hydrochloride is expected to be available between 2029 and 2030. None is for sale yet.
Why 2029 to 2030?
The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. We rate it toss-up: still unsettled. Just as likely to slip as to hold.
If Iclusig’s last patent runs to December 2033, how can a generic come sooner?
The 4 patents that run past the expected month, to December 2033 (9,493,470, 11,192,895, 11,192,897 and 11,384,086), cover the active ingredient, the product’s formulation and a way of using it. A generic can still come sooner if a court rules a patent invalid or not infringed, or if the companies settle on an earlier date. Its FDA protection (orphan drug) also runs past the expected month, to March 2031. That protection covers only the use it was granted for, so a generic may be able to launch for other uses and leave that one off its label. Here, a settlement between the companies sets the date. Generic companies have been challenging Iclusig’s patents with the FDA since March 2021. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, and more so as more companies sell one. 3 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 44% less once two companies sold a generic. See the price pattern
What should I do now?
Keep taking Iclusig as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Iclusig by the Numbers
- Reason
- Settlement between companiesThe brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
- How sure
- Toss-up Still unsettled. Just as likely to slip as to hold.
- Price competition
- Moderate 3 companies have filed, 1 first in line
- Brand sales
- $428M a yearBig seller
- FDA approved 2012 December 2012 FDA Orange Book
- Patents listed 6 last runs to December 2033 A generic is expected sooner, between 2029 and 2030. See why FDA Orange Book
- Medicare Part D spent $221.1M in 2025, for 1,318 people CMS Part D Spending by Drug
- Medicaid prescriptions 2,480 in the last four reported quarters, $56.4M CMS Medicaid drug utilization, to Q1 2026
Iclusig’s Road to a Generic
Iclusig has had the market to itself since the FDA approved it in December 2012 (Takeda Pharmaceuticals USA Inc). Its FDA protection (orphan drug) runs to March 2031. Its 6 listed patents run to December 2033. Generic companies have challenged its patents with the FDA since March 2021.
The first generic of Iclusig is expected between 2029 and 2030.
Why that month: the brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
Why a Generic Can Come Before December 2033
The last listed patent runs to December 2033; a court ruling or a settlement can bring a generic sooner. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Iclusig Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Iclusig’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 9,029,533 | A way of using it (U-1283, U-1700, U-1701, U-836, U-1699) | December 2026 | Active |
| 8,114,874 | The active ingredient; the product’s formulation | January 2027 | Active |
| 9,493,470 | The active ingredient; the product’s formulation; a way of using it (U-1700, U-1948) | December 2033 | Active |
| 11,192,895 | A way of using it (U-1700, U-1701, U-1948) | December 2033 | Active |
| 11,192,897 | The active ingredient; a way of using it (U-1700, U-1701, U-1948) | December 2033 | Active |
| 11,384,086 | The active ingredient; the product’s formulation; a way of using it (U-1700, U-1948, U-1701) | December 2033 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New use I-934 | Three years of protection for a newly approved use (indication). | March 2027 | Active |
| Orphan drug ODE-472 | Seven years of protection for a use in a rare disease. | March 2031 | Active |
Source: FDA Orange Book, application 203469. Patent numbers open the patent on Google Patents.
Patent Challenges to Iclusig
The first patent challenge to Iclusig reached the FDA in March 2021, from one company on that first day. The FDA’s list has 2 entries for Iclusig, by form and strength. The FDA approved a first challenger’s generic in July 2023, and the list records no sale by a first challenger yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Iclusig’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Tablets, 15 mg and 45 mg | March 2021 | 1 company | First challenger eligible decided August 2023 | July 2023 | Not yet | December 2033 |
| Tablets, 10 mg and 30 mg | December 2022 | 1 company | No decision yet | Not yet | Not yet | December 2033 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Ponatinib Hydrochloride
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
3 companies have applied to the FDA to make generic ponatinib hydrochloride.
The FDA names a company only once it approves its application, even tentatively, and it has not done that for these yet, so the companies are not named here. Names often come out in the brand company’s patent lawsuits or in the companies’ own announcements.
First in line. One of them was first in line: the first company to challenge the brand’s patents can earn 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Iclusig’s patents with the FDA since March 2021: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic ponatinib hydrochloride. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic ponatinib hydrochloride for sale with the FDA.
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Apotex Inc discontinued | July 2023 | EQ 15MG BASE, EQ 45MG BASE | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Iclusig Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Iclusig, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Iclusig
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Iclusig, before manufacturer rebates.
- $61.3M
- January to March 2026, the latest CMS has posted
For 1,045 people, about $23,085 per prescription fill - $221.1M
- 2025, the whole year
For 1,318 people, about $22,433 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $61,266,678 | 1,045 | $23,084.66 |
| 2025 | $221,056,119 | 1,318 | $22,433.14 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Iclusig only, so no generic is counted in it. What CMS says it is used for: Ponatinib is used to treat certain types of blood cancer (chronic myelogenous leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells.
Medicaid Prescriptions by Quarter
2,480 prescriptions in the four quarters to Q1 2026, $56.4M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 507 | $12,317,012 |
| Q4 2025 | 651 | $14,794,974 |
| Q3 2025 | 704 | $15,763,301 |
| Q2 2025 | 618 | $13,532,208 |
| Q1 2025 | 636 | $14,250,924 |
Source: CMS Medicaid State Drug Utilization Data, over Iclusig’s own package codes.
Iclusig Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 15MG BASE | Tablet | Oral | December 2012 | Prescription reference product |
| EQ 45MG BASE | Tablet | Oral | December 2012 | Prescription reference product |
| EQ 30MG BASE | Tablet | Oral | April 2015 | Prescription reference product |
| EQ 10MG BASE | Tablet | Oral | December 2020 | Prescription reference product |
Source: FDA Orange Book, Takeda Pharmaceuticals USA Inc. Listed for sale today by Takeda Pharmaceuticals America, Inc. (FDA NDC Directory).
Iclusig NDC Codes and Packages
Each Iclusig package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 63020-0536-30 | PONATINIB HYDROCHLORIDE 10 mg/1 tablet, film coated | bottle of 30 tablets | Takeda Pharmaceuticals America, Inc. |
| 63020-0536-30 | PONATINIB HYDROCHLORIDE 10 mg/1 tablet, film coated | bottle of 30 tablets | Takeda Pharmaceuticals America, Inc. |
| 63020-0535-30 | PONATINIB HYDROCHLORIDE 15 mg/1 tablet, film coated | bottle of 30 tablets | Takeda Pharmaceuticals America, Inc. |
| 63020-0535-30 | PONATINIB HYDROCHLORIDE 15 mg/1 tablet, film coated | bottle of 30 tablets | Takeda Pharmaceuticals America, Inc. |
| 63020-0535-60 | PONATINIB HYDROCHLORIDE 15 mg/1 tablet, film coated | bottle of 60 tablets | Takeda Pharmaceuticals America, Inc. |
| 63020-0535-60 | PONATINIB HYDROCHLORIDE 15 mg/1 tablet, film coated | bottle of 60 tablets | Takeda Pharmaceuticals America, Inc. |
| 63020-0533-30 | PONATINIB HYDROCHLORIDE 30 mg/1 tablet, film coated | bottle of 30 tablets | Takeda Pharmaceuticals America, Inc. |
| 63020-0533-30 | PONATINIB HYDROCHLORIDE 30 mg/1 tablet, film coated | bottle of 30 tablets | Takeda Pharmaceuticals America, Inc. |
| 63020-0534-30 | PONATINIB HYDROCHLORIDE 45 mg/1 tablet, film coated | bottle of 30 tablets | Takeda Pharmaceuticals America, Inc. |
| 63020-0534-30 | PONATINIB HYDROCHLORIDE 45 mg/1 tablet, film coated | bottle of 30 tablets | Takeda Pharmaceuticals America, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Iclusig’s own FDA approval (NDA 203469) are listed, never a generic. Some codes belong to companies that repackage Iclusig: it is the same medicine in a different package.
What a Generic Iclusig Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Iclusig as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Iclusig”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Iclusig
Is there a generic for Iclusig right now?
No. As of October 9, 2026 no generic ponatinib hydrochloride is listed for sale in the FDA NDC Directory. 1 generic version is FDA-approved (Orange Book), which usually means it is waiting on patents or on the maker’s own launch plans.
When will Iclusig go generic?
2029 to 2030 is the expected window, and that is toss-up but not certain. The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. The last listed patent runs to December 2033; a court ruling or a settlement can bring a generic sooner.
Will generic ponatinib hydrochloride be the same as Iclusig?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. 3 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 44% less once two companies sold a generic. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Iclusig?
Not yet. The FDA Orange Book lists no approved generic version of Iclusig that is still marketed.
When does the Iclusig patent expire?
The FDA Orange Book lists 6 patents for Iclusig; the last runs to December 2033. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (2029 to 2030) weighs all of that.
Has anyone challenged the Iclusig patents?
Yes. The first patent challenge to Iclusig reached the FDA in March 2021, from one company on that first day. The FDA approved a first challenger’s generic in July 2023, and the list records no sale by a first challenger yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
Changes to This Projection
- First generic expected 2029 to 2030 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- OtrexupMethotrexateMay 2031
- KorsuvaDifelikefalin AcetateJuly to December 2032
- Esmolol HydrochlorideEsmolol HydrochlorideMarch 2033
- XdemvyLotilaner2036 to 2037
- BarhemsysAmisulprideFebruary 2038
- SyndrosDronabinolTBD no date yet
About Iclusig
- Generic name ponatinib hydrochloride
- How it is taken By mouth
- Company Takeda Pharmaceuticals USA Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- Patent challenges Since March 2021 (FDA)
- More drugs Brand-name drugs starting with I
- Have a question? A pharmacist answers, free. Ask about Iclusig
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.